CDCN and COVID-19

CORONA (COvid19 Registry of Off-label & New Agents)

Drug Repurposing for COVID-19

Our overarching vision:  A world where data on all treatments that have been used against COVID19 are maintained in a central repository and analyzed so that physicians currently treating COVID19 patients know what treatments are most likely to help their patients and so that clinical trials can be appropriately prioritized.

Phase 1: COMPLETED

Our team reviewed 2500+ papers & extracted data on over 9,000 COVID19 patients. We found 115 repurposed drugs that have been used to treat COVID19 patients and analyzed data on which ones seem most promising for clinical trials. This data is open source and can be used by physicians to treat patients and prioritize drugs for trials. The CDCN will keep this database updated as a resource for this global fight. Repurposed drugs give us the best chance to help COVID19 as quickly as possible! As disease hunters who have identified and repurposed drugs for Castleman disease, we’re applying our ChasingMyCure approach to COVID19.

Read our systematic literature review published in Infectious Diseases and Therapy at the following link: Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review

Read the Press Release from PennMedicine at the following link: PennMedicine Press Release

Phase 2: Continue to update CORONA

Our team continues to work diligently to maintain an updated listing of all treatments reported to be used in COVID19 patients from papers in PubMed. We are also re-analyzing publicly available COVID19 single cell transcriptomic data alongside our iMCD data to search for novel insights and therapeutic targets.

You can visit the following link to access a database viewer built and managed by Matt Chadsey, owner of Nonlinear Ventures.  

We are excited to share CORONA Insights, a page where we will periodically share posts summarizing key findings uncovered in the CORONA database.

If you are a physician treating COVID19 patients, please visit the FDA’s CURE ID app to report de-identified information about drugs you’ve used to treat COVID19 in just a couple minutes.

Click here for up-to-date treatment guidelines from the NIH.

For synthesized data specifically on COVID-19 and cancer, please see the Reboot: COVID-Cancer Project

Check out the following links for more information about CORONA:

Dr. Fajgenbaum describing the CORONA project on Fresh Air.

Dr. Fajgenbaum describing the CORONA project on 6ABC.

Dr. Fajgenbaum describing the CORONA project on KTLA.

Dr. Fajgenbaum describing the CORONA project on FOX5.

Dr. Fajgenbaum describing the CORONA project on ABC7.

Dr. Fajgenbaum describing the CORONA project on WRAL.

Dr. Fajgenbaum describing the CORONA project at UPENN.

 

CORONA project highlighted in the Boston Globe.

CORONA project highlighted by Diane Sawyer on 20/20.

CORONA project highlighted by CNN.

 

Please email johnson.khor@pennmedicine.upenn.edu if you are interested in contributing to this project by reviewing through published papers and extracting out information about drugs being used to treat COVID19.

Or, if you’d prefer, you can donate to support and enable this critical work at https://cdcn.org/join-the-fight/donate/

Acknowledgments:

We are grateful to our current team members who have taken on this urgent need:

David Fajgenbaum, CSTL Director
Johnson Khor, CSTL Coordinator and COVID19 Project Lead
Sheila Pierson, CSTL Clinical Research Director
Ruth-Anne Langan, PhD Student and COVID19 Data Analyst
Alek Gorzewski, ACCELERATE Data Analyst and COVID19 Data Analyst
Mileva Repasky, CDCN Chief Patient and Development Officer and COVID19 Data Analyst
Joseph Kakkis, UPenn BS Candidate and COVID19 Data Analyst
Madison McCarthy, Brown University BS Candidate and COVID19 Data Analyst
Anne Taylor, OSU MD Candidate and COVID19 Data Analyst

Erin Napier, University of Hawaii MD Candidate and COVID19 Data Analyst
Lia Keyser, Brown University BA Recipient and COVID19 Data Analyst
Dr. Duncan Mackay, PennMedicine Physician and COVID19 Data Analyst
Alex Beschloss, UPenn MD Candidate and COVID19 Data Analyst
Anna WingUPenn MD Candidate and COVID19 Data Analyst
Ashwin AmurthurUPenn MD Candidate and COVID19 Data Analyst
Beatrice GoUPenn MD Candidate and COVID19 Data Analyst
Casey KimUPenn MD Candidate and COVID19 Data Analyst
James GermiUPenn MD Candidate and COVID19 Data Analyst
Joanna JiangUPenn MD Candidate and COVID19 Data Analyst
Laura MiyarnesUPenn MD Candidate and COVID19 Data Analyst
Michael MayerUPenn MD Candidate and COVID19 Data Analyst
Philip AngelidesUPenn MD Candidate and COVID19 Data Analyst
Sarah FranklUPenn MD Candidate and COVID19 Data Analyst
Vivek NimgaonkarUPenn MD Candidate and COVID19 Data Analyst
Steve Bambury, University of Pittsburg BS Candidate and COVID19 Data Analyst
Nick Goodyear, Temple University BS Candidate and COVID19 Data Analyst 

We are grateful to our Phase II team members who have continued this important work:
Alex Beschloss, Anne Taylor, Ashwin Armurthur, Aura Enache, Beatrice Go, Biliana Rotse, Bruna Martins, Cheng Cheng, David Bright, Derek Ansel, Dorothy Kenny, Edward Shadiack, Evaggelia Nassis, Florence Porterfield, Gary Gravina, Hadis Williams. Heather Farley, Helen Eisenach, James Germi, Jayson Wisk, Jenna Pacheco, Joanna Jiang, Joseph Kakkis, Joshua Deffenbaugh, Karen Gunderson, Kate Chang, Kevin Freiert, Kristen Stegeland, Lindsay Muratore, Maggie Reilly, Margareta Sorenson, Matt Pepper, Megan Fisher, Meggie Goodridge, Meryt Hanna, Monica Lucurara, Nicole Engelhardt, Philip Angelides, Philip Rybczynski, Sarah Frankl, Sarah VanFleet, Shah Makujina, Trisha Paryil, Vivek Nimgaonkar

Partners:

Doctor Evidence’s (DRE) platform enables researchers to identify and discover evidence for analysis to generate actionable data insights far beyond human capabilities. The recent Coronavirus pandemic has shown the world the ever-increasing need to process voluminous amounts of data in real-time.  DRE is happy to support Dr. Fajgenbaum and his team’s vision for finding a COVID-19 cure through a systematic literature review.

 

Matt Chadsey founded Nonlinear Ventures to help communities and organizations leverage best practices in systems thinking, portfolio management, economic valuation, and data visualization to make better investments in communities and the environment. He is excited to support the work of CDCN and help make its innovative research accessible worldwide!

Arrow Shape Facebook Instagram Twitter Youtube Play Arrow Left